Symptomatic treatment of benign prostatic obstruction with Nicergoline

A placebo controlled clinical study and urodynamic evaluation

F. Ronchi, A. Margonato, R. Ceccardi, P. Rigatti, B. M. Rossini

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A double-blind crossover study of the alphablocker Nicergoline was carried out in sixteen patients affected by benign prostatic bladder outflow obstruction. The "irritative" symptoms of prostatic hypertrophy, including nocturnal frequency and dysuria, were improved after Nicergoline significantly more than after placebo. In 10 further patients with prostatic hypertrophy, peak and mean flow rates increased by 50% and 77% respectively after the acute administration of Nicergoline. No side effects were detected. In conclusion Nicergoline seems to be active and well tolerated in the treatment of benign prostatic obstruction.

Original languageEnglish
Pages (from-to)131-134
Number of pages4
JournalUrological Research
Volume10
Issue number3
DOIs
Publication statusPublished - Aug 1982

Fingerprint

Nicergoline
Urodynamics
Placebos
Prostatic Hyperplasia
Dysuria
Therapeutics
Double-Blind Method
Cross-Over Studies
Urinary Bladder
Clinical Studies

Keywords

  • Benign prostatic obstruction
  • Nicergoline
  • Urodynamic evaluation

ASJC Scopus subject areas

  • Urology

Cite this

Symptomatic treatment of benign prostatic obstruction with Nicergoline : A placebo controlled clinical study and urodynamic evaluation. / Ronchi, F.; Margonato, A.; Ceccardi, R.; Rigatti, P.; Rossini, B. M.

In: Urological Research, Vol. 10, No. 3, 08.1982, p. 131-134.

Research output: Contribution to journalArticle

@article{b08652d2a64d42e3ba4ecafc927c3adf,
title = "Symptomatic treatment of benign prostatic obstruction with Nicergoline: A placebo controlled clinical study and urodynamic evaluation",
abstract = "A double-blind crossover study of the alphablocker Nicergoline was carried out in sixteen patients affected by benign prostatic bladder outflow obstruction. The {"}irritative{"} symptoms of prostatic hypertrophy, including nocturnal frequency and dysuria, were improved after Nicergoline significantly more than after placebo. In 10 further patients with prostatic hypertrophy, peak and mean flow rates increased by 50{\%} and 77{\%} respectively after the acute administration of Nicergoline. No side effects were detected. In conclusion Nicergoline seems to be active and well tolerated in the treatment of benign prostatic obstruction.",
keywords = "Benign prostatic obstruction, Nicergoline, Urodynamic evaluation",
author = "F. Ronchi and A. Margonato and R. Ceccardi and P. Rigatti and Rossini, {B. M.}",
year = "1982",
month = "8",
doi = "10.1007/BF00255955",
language = "English",
volume = "10",
pages = "131--134",
journal = "Urological Research",
issn = "0300-5623",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Symptomatic treatment of benign prostatic obstruction with Nicergoline

T2 - A placebo controlled clinical study and urodynamic evaluation

AU - Ronchi, F.

AU - Margonato, A.

AU - Ceccardi, R.

AU - Rigatti, P.

AU - Rossini, B. M.

PY - 1982/8

Y1 - 1982/8

N2 - A double-blind crossover study of the alphablocker Nicergoline was carried out in sixteen patients affected by benign prostatic bladder outflow obstruction. The "irritative" symptoms of prostatic hypertrophy, including nocturnal frequency and dysuria, were improved after Nicergoline significantly more than after placebo. In 10 further patients with prostatic hypertrophy, peak and mean flow rates increased by 50% and 77% respectively after the acute administration of Nicergoline. No side effects were detected. In conclusion Nicergoline seems to be active and well tolerated in the treatment of benign prostatic obstruction.

AB - A double-blind crossover study of the alphablocker Nicergoline was carried out in sixteen patients affected by benign prostatic bladder outflow obstruction. The "irritative" symptoms of prostatic hypertrophy, including nocturnal frequency and dysuria, were improved after Nicergoline significantly more than after placebo. In 10 further patients with prostatic hypertrophy, peak and mean flow rates increased by 50% and 77% respectively after the acute administration of Nicergoline. No side effects were detected. In conclusion Nicergoline seems to be active and well tolerated in the treatment of benign prostatic obstruction.

KW - Benign prostatic obstruction

KW - Nicergoline

KW - Urodynamic evaluation

UR - http://www.scopus.com/inward/record.url?scp=0019959273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019959273&partnerID=8YFLogxK

U2 - 10.1007/BF00255955

DO - 10.1007/BF00255955

M3 - Article

VL - 10

SP - 131

EP - 134

JO - Urological Research

JF - Urological Research

SN - 0300-5623

IS - 3

ER -